• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    MBX Biosciences Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    6/9/25 7:59:27 AM ET
    $MBX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MBX alert in real time by email
    8-K
    false000177611100017761112025-06-092025-06-09

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): June 09, 2025

     

     

    MBX Biosciences, Inc.

    (Exact name of Registrant as Specified in Its Charter)

     

     

    Delaware

    001-42272

    84-1882872

    (State or Other Jurisdiction
    of Incorporation)

    (Commission File Number)

    (IRS Employer
    Identification No.)

     

     

     

     

     

    11711 N. Meridian Street

    Suite 300

     

    Carmel, Indiana

     

    46032

    (Address of Principal Executive Offices)

     

    (Zip Code)

     

    Registrant’s Telephone Number, Including Area Code: (317) 659-0200

     

    Not Applicable

    (Former Name or Former Address, if Changed Since Last Report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:


    Title of each class

     

    Trading
    Symbol(s)

     


    Name of each exchange on which registered

    Common Stock, $0.0001 par value per share

     

    MBX

     

    Nasdaq Global Select Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     


    Item 7.01 Regulation FD Disclosure

    On June 9, 2025, MBX Biosciences, Inc. posted to the "Investors" section of the Company's website at www.mbxbio.com an updated corporate presentation. A copy of the Corporate Presentation is attached hereto as Exhibit 99.1 and is incorporated by reference into this Item 7.01 of this Current Report on Form 8-K.

     

    The information contained in this Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

    Item 9.01 Financial Statements and Exhibits.

    (d) Exhibits

     

    Exhibit No.

     

    Description

     

    99.1

     

    Corporate Presentation dated June 9, 2025

     

    104

     

    Cover Page Interactive Data File (embedded within the Inline XBRL document)

     

     


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

     

     

    MBX Biosciences, Inc.

     

     

     

     

    Date:

    June 9, 2025

    By:

    /s/ P. Kent Hawryluk

     

     

     

    President and Chief Executive Officer (Principal Executive Officer)

     


    Get the next $MBX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MBX

    DatePrice TargetRatingAnalyst
    1/28/2026$66.00Overweight
    Barclays
    12/4/2025$18.00Sell
    Goldman
    11/4/2025Buy
    TD Cowen
    10/15/2025$50.00Buy
    Truist
    8/15/2025$36.00Buy
    Jefferies
    8/5/2025$38.00Outperform
    Mizuho
    7/16/2025$38.00Outperform
    Oppenheimer
    4/10/2025$38.00Mkt Outperform
    Citizens JMP
    More analyst ratings

    $MBX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    MBX Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    CARMEL, Ind., April 03, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced the issuance of an equity inducement award to Karen Basbaum in connection with her commencement of employment as the company's new Chief Business Officer. The inducement award consisted of non-qualified stock options to purchase an aggregate of 130,000 shares of the company's common stock with an exercise price of $32.29 per share, which is equal to the closing price of the company's common stock

    4/3/26 8:00:00 AM ET
    $MBX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MBX Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Corporate Highlights

    Phase 3 trial of once-weekly canvuparatide remains on track to initiate in Q3 2026 following recently completed, successful End-of-Phase 2 meeting with FDA 12-week MAD Phase 1 data from MBX 4291 for obesity anticipated in Q4 2026 Planned nomination of amycretin and GLP-1/GIP/glucagon receptor triple-agonist development candidates for obesity expected in Q2 and Q3 2026 $459.1 million in pro forma cash and investments as of December 31, 2025, including $85.4 million in net proceeds from top-tier institutional investors through ATM program; expected to support operations into 2029 CARMEL, Ind., March 12, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stag

    3/12/26 8:00:00 AM ET
    $MBX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MBX Biosciences Appoints Karen Basbaum as Chief Business Officer

    CARMEL, Ind., March 10, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced the appointment of Karen Basbaum, MBA, as Chief Business Officer (CBO). Ms. Basbaum brings more than two decades of leadership in corporate strategy, business development, and strategic transactions across the biotechnology and pharmaceutical industries. "Karen is a highly accomplished and strategic leader with a proven track record of sourcing, structuring, and executing high-value partnerships

    3/10/26 8:00:00 AM ET
    $MBX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MBX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Smither John W

    3 - MBX Biosciences, Inc. (0001776111) (Issuer)

    3/18/26 4:05:03 PM ET
    $MBX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President & CEO Hawryluk P. Kent bought $525,663 worth of shares (18,500 units at $28.41) (SEC Form 4)

    4 - MBX Biosciences, Inc. (0001776111) (Issuer)

    3/16/26 8:02:03 AM ET
    $MBX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President & CEO Hawryluk P. Kent exercised 28,768 shares at a strike of $16.00, increasing direct ownership by 4% to 728,274 units (SEC Form 4)

    4 - MBX Biosciences, Inc. (0001776111) (Issuer)

    2/27/26 4:07:02 PM ET
    $MBX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MBX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Barclays initiated coverage on MBX Biosciences with a new price target

    Barclays initiated coverage of MBX Biosciences with a rating of Overweight and set a new price target of $66.00

    1/28/26 7:18:07 AM ET
    $MBX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Goldman initiated coverage on MBX Biosciences with a new price target

    Goldman initiated coverage of MBX Biosciences with a rating of Sell and set a new price target of $18.00

    12/4/25 8:45:53 AM ET
    $MBX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TD Cowen initiated coverage on MBX Biosciences

    TD Cowen initiated coverage of MBX Biosciences with a rating of Buy

    11/4/25 7:44:06 AM ET
    $MBX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MBX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President & CEO Hawryluk P. Kent bought $525,663 worth of shares (18,500 units at $28.41) (SEC Form 4)

    4 - MBX Biosciences, Inc. (0001776111) (Issuer)

    3/16/26 8:02:03 AM ET
    $MBX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President & CEO Hawryluk P. Kent bought $272,790 worth of shares (20,000 units at $13.64) (SEC Form 4)

    4 - MBX Biosciences, Inc. (0001776111) (Issuer)

    10/21/25 5:43:44 PM ET
    $MBX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Hoerter Steven L. bought $264,984 worth of shares (20,000 units at $13.25) (SEC Form 4)

    4 - MBX Biosciences, Inc. (0001776111) (Issuer)

    10/20/25 4:44:37 PM ET
    $MBX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MBX
    SEC Filings

    View All

    SEC Form 144 filed by MBX Biosciences Inc.

    144 - MBX Biosciences, Inc. (0001776111) (Subject)

    3/25/26 3:20:43 PM ET
    $MBX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by MBX Biosciences Inc.

    144 - MBX Biosciences, Inc. (0001776111) (Subject)

    3/16/26 2:47:39 PM ET
    $MBX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-3ASR filed by MBX Biosciences Inc.

    S-3ASR - MBX Biosciences, Inc. (0001776111) (Filer)

    3/12/26 4:07:02 PM ET
    $MBX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MBX
    Leadership Updates

    Live Leadership Updates

    View All

    MBX Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Corporate Highlights

    Phase 3 trial of once-weekly canvuparatide remains on track to initiate in Q3 2026 following recently completed, successful End-of-Phase 2 meeting with FDA 12-week MAD Phase 1 data from MBX 4291 for obesity anticipated in Q4 2026 Planned nomination of amycretin and GLP-1/GIP/glucagon receptor triple-agonist development candidates for obesity expected in Q2 and Q3 2026 $459.1 million in pro forma cash and investments as of December 31, 2025, including $85.4 million in net proceeds from top-tier institutional investors through ATM program; expected to support operations into 2029 CARMEL, Ind., March 12, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stag

    3/12/26 8:00:00 AM ET
    $MBX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MBX Biosciences Appoints Karen Basbaum as Chief Business Officer

    CARMEL, Ind., March 10, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced the appointment of Karen Basbaum, MBA, as Chief Business Officer (CBO). Ms. Basbaum brings more than two decades of leadership in corporate strategy, business development, and strategic transactions across the biotechnology and pharmaceutical industries. "Karen is a highly accomplished and strategic leader with a proven track record of sourcing, structuring, and executing high-value partnerships

    3/10/26 8:00:00 AM ET
    $MBX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MBX Biosciences Appoints Laurie Stelzer to Board of Directors as Audit Committee Chair

    CARMEL, Ind., Jan. 22, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced the appointment of Laurie Stelzer as an independent director on the Company's Board of Directors and as chairperson of the board's audit committee. Ms. Stelzer brings decades of executive and financial leadership experience with extensive corporate governance, financial oversight, and accounting experience. "I am thrilled to welcome Laurie Stelzer to the Company's Board as an independent director,"

    1/22/26 8:00:00 AM ET
    $MBX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MBX
    Financials

    Live finance-specific insights

    View All

    MBX Biosciences Announces Once-Weekly Canvuparatide Achieved Primary Endpoint in Phase 2 Trial with 63% Responder Rate at 12 Weeks; 79% Responder Rate at 6 Months in Open-Label Extension

    Statistically significant responder rate achieved at 12 weeks with zero contribution from rescue therapy (PRN) and further improvement sustained in open-label extension (OLE) Positive findings in bone and kidney biomarkers All patients completed the 12-week AvailTM trial and 94% entered the OLE Once-weekly canvuparatide was generally well tolerated, with no treatment-related serious adverse events or discontinuations during the 12-week trial Preparation underway to initiate Phase 3 trial in 2026 Company to host conference call at 8:00 am ET today CARMEL, Ind., Sept. 22, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stage biopharmaceutical company focused on

    9/22/25 7:00:00 AM ET
    $MBX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MBX Biosciences to Provide Topline Results from its Phase 2 Trial of Potential Once-Weekly Canvuparatide for Hypoparathyroidism (HP) on Monday, September 22

    CARMEL, Ind., Sept. 19, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that it will provide topline results from its Phase 2 clinical trial of potential once-weekly canvuparatide for patients with chronic hypoparathyroidism (HP) and host an investor webcast on Monday, September 22. The Company will host a conference call and webcast at 8 am ET on Monday, September 22 to discuss the results from the Avail™ Phase 2 trial. Those who would like to participate may access the live webcast he

    9/19/25 4:18:59 PM ET
    $MBX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MBX Biosciences Announces Positive Phase 1 Topline Results for MBX 1416 for the Treatment of Post-bariatric Hypoglycemia

    Phase 1 results support proceeding to Phase 2 in patients with post-bariatric hypoglycemia (PBH), which is expected to begin in 2H 2025 Phase 1 trial in healthy volunteers showed MBX 1416 was generally well-tolerated with a favorable safety profile Pharmacokinetic results demonstrated sustained dose-dependent exposure and support once-weekly dosing Company to host conference call to discuss results today at 8:30 am ET CARMEL, Ind., Jan. 07, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today annou

    1/7/25 7:00:00 AM ET
    $MBX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MBX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by MBX Biosciences Inc.

    SC 13G - MBX Biosciences, Inc. (0001776111) (Subject)

    11/8/24 10:52:39 AM ET
    $MBX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by MBX Biosciences Inc.

    SC 13G - MBX Biosciences, Inc. (0001776111) (Subject)

    11/1/24 5:38:56 PM ET
    $MBX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D filed by MBX Biosciences Inc.

    SC 13D - MBX Biosciences, Inc. (0001776111) (Subject)

    9/23/24 6:07:21 PM ET
    $MBX
    Biotechnology: Pharmaceutical Preparations
    Health Care